It implies that small molecule inhibitor MM-401 inhibits MLLr leukemia by two compatible modes of actions: blocking MLL1 methyltransferase activity and disrupting MLL1 complex integrity at a significant subset of MLL1 targets. Here, KMT2A is linked to leukemia.